<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01142934</url>
  </required_header>
  <id_info>
    <org_study_id>TegaCHGit01</org_study_id>
    <nct_id>NCT01142934</nct_id>
  </id_info>
  <brief_title>Trial on the Efficacy of Tegaderm Chlorhexidine Gluconate (CHG) in Reducing Catheter Related Bloodstream Infections</brief_title>
  <acronym>TegaCHG</acronym>
  <official_title>A MULTICENTRE RANDOMIZED CONTROLLED CLINICAL TRIAL ON THE EFFICACY OF TEGADERM CHG IN REDUCING CATHETER RELATED BLOOD STREAM INFECTIONS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>3M</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione C.N.R./Regione Toscana &quot;G. Monasterio&quot;, Pisa, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      TegaCHG is a multicentric randomized study aimed at evaluating the possibility that the use
      of TegaDerm CHG dressing may reduce the incidence of catheter related blood stream infections
      (CRBSI). It implies the comparison between the incidence of CRBSI in patients with central
      venous catheter dressed with TegaDerm without chlorhexidine gluconate (CHG) and with CHG. The
      primary endpoint is the occurrence of CRBSI and the secondary endpoints are:

      catheter colonization (growth of microbes from the culture of catheter tip, &gt; 15 CFU
      according to semi-quantitative method or &gt; 1000 CFU according to quantitative method);
      incidence of catheter exit site infection; occurrence of catheter related infections/sepsis
      or other severe infection-related complications; safety profile evaluation: occurrence of
      hypersensitivity to the dressing on the basis of local objectivity (erythema, edema, other)
      or on that of patient symptoms (itch, burning sensation); relating to the device performance:
      incidence of high/medium/low dressing edge lift, ability to visualize the catheter insertion
      site, easiness of removal, easiness of dressing application; incidence of unscheduled
      dressing change. The study hypothesis implies that the use of slow release device containing
      chlorhexidine may decrease the incidence of CRBSI. This has already been showed for
      chlorhexidine impregnated sponges. Scope of the study is to verify if this property is also
      true for TegaDerm CHG,which is a new chlorhexidine-releasing dressing in which the medication
      is directly released by an integrated transparent gel pad, so that the catheter exit site
      remains visible and easy to inspect without removing the dressing.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">October 2012</completion_date>
  <primary_completion_date type="Anticipated">April 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of catheter-related bloodstream infection</measure>
    <time_frame>Up to 7 days after catheter removal</time_frame>
    <description>According to the definition of CRBSI suggested in &quot;Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America&quot; (Clin Infect Dis 2009; 49:1-45)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 2 days after catheter removal</time_frame>
    <description>Other Secondary Outcome Measures are represented by: determining whether TegadermTM CHG decreases catheter colonization; determining whether TegadermTM CHG decreases the incidence of catheter site infection; evaluating patient comfort; to evaluate overall nursing satisfaction (ease of dressing application, incidence of dressing edge lift, ability to visualize the catheter insertion site, ease of removal); determining whether TegadermTM CHG decreases the incidence of unscheduled dressing change compared to the control group.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Catheterization</condition>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>TegaDerm CHG</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>TegaDerm CHG is the interventional arm to be compared with the control group in which the dressing is TegaDerm (without CHG).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transparent adhesive dressing with an integrated gel pad containing 2% w/w chlorhexidine gluconate (CHG) (TegaDerm CHG)</intervention_name>
    <description>The intervention is represented by the combination of the TegaDerm transparent adhesive dressing with an integrated gel pad containing 2% w/w chlorhexidine gluconate (CHG), an antiseptic agent with broad spectrum antimicrobial and antifungal activity.</description>
    <arm_group_label>TegaDerm CHG</arm_group_label>
    <other_name>TegaDerm CHG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Hospitalized patients, either in Intensive Care Unit or in non-Intensive Care ward
             settings

          -  Clinical indication for the insertion of a non-tunneled central venous catheter
             (excluding large bore catheters for dialysis or pheresis) or a PICC

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Inability to obtain an informed consent

          -  Actual evidence - or recent history (&lt; 30 days) - of bloodstream infection

          -  Central lines inserted in the femoral vein

          -  Central lines inserted by surgical cutdown

          -  Use of so called 'treated' catheters, i.e. catheters whose internal and/or external
             surface is coated with antibacterial drugs as well as catheters whose polyurethane
             releases ions with potential antiseptic action, should be excluded by the present
             protocol

          -  Specific intolerance or known hypersensitivity to transparent dressings or to
             chlorhexidine

          -  Any form of dermatitis, burns, skin lesions or tattoos at the insertion site

          -  Burns over ≥ 15% of the body surface area

          -  Use of topical antibiotics within a 10cm of the catheter insertion site

          -  Enrollment in another investigational drug or device study at any time during this
             study or 30 days prior.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giancarlo Scoppettuolo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dpt. Infectious Diseases, Rome Catholic University (CUSacredHeart)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mauro Pittiruti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dpt. Surgery, Rome Catholic University (CUSacredHeart)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giancarlo Scoppettuolo, MD</last_name>
    <phone>+393498380576</phone>
    <email>g.scoppettuolo@rm.unicatt.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mauro Pittiruti, MD</last_name>
    <phone>+393388514032</phone>
    <email>mauro.pittiruti@rm.unicatt.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>I.C.U. Ospedale Civico</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zina Picciuca, RN</last_name>
      <email>zina@ospedalecivicopa.org</email>
    </contact>
    <investigator>
      <last_name>Zina Picciuca, RN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dpt. Infectious Diseases, Rome Catholic University</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giancarlo Scoppettuolo, MD</last_name>
      <phone>+393498380576</phone>
      <email>g.scoppettuolo@rm.unicatt.it</email>
    </contact>
    <contact_backup>
      <last_name>Laura Dolcetti, RN</last_name>
      <phone>+393336157080</phone>
      <email>laura.dolcetti@libero.it</email>
    </contact_backup>
    <investigator>
      <last_name>Laura Dolcetti, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giancarlo Scoppettuolo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>I.C.U. Rome Catholic University</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Mencio, RN</last_name>
      <email>vincenzomencio@interfree.it</email>
    </contact>
    <investigator>
      <last_name>Vincenzo Mencio, RN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Surgery Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanna Sodo, RN</last_name>
      <email>s.sodo@policlinicoumberto1.it</email>
    </contact>
    <investigator>
      <last_name>Susanna Sodo, RN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>I.C.U. Heart Surgery Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanna Sodo, RN</last_name>
      <email>s.sodo@policlinicoumberto1.it</email>
    </contact>
    <investigator>
      <last_name>Susanna Sodo, RN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>I.C.U. Neurosurgery Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanna Sodo, RN</last_name>
      <email>s.sodo@policlinicoumberto1.it</email>
    </contact>
    <investigator>
      <last_name>Susanna Sodo, RN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>I.C.U. Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanna Sodo, RN</last_name>
      <email>s.sodo@policlinicoumberto1.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Palliative Car Unit - Ospedale di Circolo</name>
      <address>
        <city>Varese</city>
        <state>VA</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniele Bertollo, MD</last_name>
      <email>dani.fabi@tin.it</email>
    </contact>
    <investigator>
      <last_name>Daniele Bertollo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.3m.com/</url>
  </link>
  <link>
    <url>http://www.gavecelt.info</url>
    <description>Italian Group for the Study of Medium and Long Term Vascular Access</description>
  </link>
  <link>
    <url>http://www.rm.unicatt.it</url>
    <description>Rome Catholic University, School of Medicine</description>
  </link>
  <link>
    <url>http://www.evanetwork.info</url>
    <description>European Vascular Access Network</description>
  </link>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2010</study_first_submitted>
  <study_first_submitted_qc>June 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2010</study_first_posted>
  <last_update_submitted>January 31, 2012</last_update_submitted>
  <last_update_submitted_qc>January 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University of the Sacred Heart</investigator_affiliation>
    <investigator_full_name>Giancarlo Scoppettuolo</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Catheter-related bloodstream infections</keyword>
  <keyword>Chlorhexidine</keyword>
  <keyword>Transparent dressings</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

